text
"['\n4. 매출 및 수주상황\n가. 매출실적\n\xa0 \xa0 \xa0 ( 단위 : 백만원)\n사업부문\n품목\n구분\n제51 분기\n제50 기\n제49 기\n산업설비공사\n산업설비플랜트E.P.C\n수출\n852\n1,723\n2,514\n내수\n39,696\n70,098\n54,274\n합계\n40,548\n71,821\n56,788\n화장품\n새라제나 등\n수출\n-\n-\n-\n내수\n342\n649\n1,948\n합계\n342\n649\n1,948\n건강식품\n스위치온 등\n수출\n-\n-\n-\n내수\n1,032\n-\n-\n합계\n1,032\n-\n-\n기타\n젠바디 등\n수출\n-\n-\n-\n내수\n37\n-\n-\n합계\n37\n-\n-\n셀론텍\n리젠씰, 카티졸, 테라필, 테라폼 등\n수출\n-\n-\n-\n내수\n-\n-\n-\n합계\n-\n-\n-\n합계\n수출\n852\n1,723\n2,514\n내수\n41,107\n70,747\n56,222\n합계\n41,959\n72,470\n58,736\n나. 판매경로 및 판매방법 등[셀론텍]동사의 바이오콜라겐 기반 생체재료는 전략적인 거래처 및 대리점 등을 통하여 판매하고 있습니다. 이와 같은 대리점 등을 통한 간접 판매방법은 동사와 같이 직영 영업조직을 운영하기 힘든 중소기업에서\xa0일반적으로 운영하는 판매방식입니다.다. 수주상황\n\xa0 \xa0 \xa0 ( 단위 : 천원 )\n구분\n기초\n증감액\n공사수익인식\n기말\n산업설비공사\n48,699,168\n100,506,637\n40,547,994\n108,657,811\n라.\xa0진행률적용 수주상황\n(단위 : 천원)\n계약처\n계약일자\n계약상완성기한\n진행율\n수주총액\n당분기공사수익인식\n수주잔고\n계약자산\n매출채권\n총액\n손상차손누계액\n총액\n대손충당금\n셀론텍㈜\n19/12/04\n22/01/31\n29%\n31,000,000\n4,082,700\n26,917,300\n-\n-\n2,202,860\n-\n금호피앤비화학㈜\n20/06/17\n21/12/31\n86%\n8,170,000\n5,188,767\n2,981,233\n80,495\n-\n546,841\n-\n티이엠씨 주식회사\n20/06/24\n21/12/31\n97%\n6,574,000\n5,278,685\n1,295,315\n312,419\n-\n224,840\n-\n롬엔드하스전자재료코리아유한\n20/07/02\n21/11/30\n99%\n6,009,648\n2,008,827\n4,000,821\n-\n-\n-\n-\n머크버슘머트리얼즈코리아㈜\n20/12/02\n21/12/31\n63%\n6,535,000\n4,052,921\n2,482,080\n240,695\n-\n1,070,850\n-\n노루홀딩스\n21/03/29\n21/12/31\n56%\n3,410,000\n1,904,144\n1,505,856\n-\n-\n501,600\n-\n금호피앤비화학㈜\n21/03/23\n21/12/31\n59%\n7,311,000\n4,296,675\n3,014,325\n-\n-\n1,515,439\n-\n스미세이케미칼㈜\n21/04/01\n22/03/31\n14%\n15,400,000\n2,106,720\n13,293,280\n-\n-\n728,420\n-\n한화솔루션\n21/04/06\n22/09/30\n8%\n32,600,000\n2,568,880\n30,031,120\n-\n-\n758,654\n-\n금호미쓰이화학㈜\n21/06/29\n22/12/31\n9%\n29,910,000\n2,727,792\n27,182,208\n-\n-\n-\n-\n삼양이노켐㈜\n21/08/18\n22/02/28\n20%\n6,540,000\n1,308,000\n5,232,000\n-\n-\n726,097\n-\n']"
